MedTrace Logo

Topical CP-690,550 For Chronic Plaque Psoriasis

NCT00678561 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2020-12-31

Study results available
· View outcomes & findings →

Summary

Study will test effectiveness of an experimental drug applied once or twice daily to two psoriasis plaques. Requires 1 clinic visit each week for 5 weeks.

Conditions

Interventions

DRUG

CP-690,550

Topical treatment once daily for 28 days

DRUG

CP-690,550

Topical treatment once daily for 28 days

DRUG

CP-690,550

Topical treatment once daily for 28 days

DRUG

CP-690,550

Topical treatment twice daily for 28 days

DRUG

CP-690,550

Topical treatment twice daily for 28 days

DRUG

CP-690,550

Topical treatment twice daily for 28 days

DRUG

Placebo Vehicle

Topical treatment once daily for 28 days

DRUG

Placebo Vehicle

Topical treatment twice daily for 28 days

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-13
Primary Completion
2009-07-09
Completion
2009-07-24

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00678561 on ClinicalTrials.gov